What Happened? A number of stocks jumped in the afternoon session after investor sentiment improved on renewed optimism that ...

BofA lowered the firm’s price target on Organon (OGN) to $11 from $15 and keeps an Underperform rating on the shares. The firm, in its preview ...

Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...

Bank of America Securities analyst Jason Gerberry maintained a Sell rating on Organon (OGN – Research Report) today and set a price target of ...

Organon announces the appointment of Ramona A. Sequeira to the company's Board of Directors, effective July 1, 2025.

In the latest market close, Organon (OGN) reached $14.56, with a -1.02% movement compared to the previous day. The stock fell short of the S&P 500, which registered a loss of 0.33% for the day.

Organon (OGN) closed at $14.45 in the latest trading session, marking a -1.83% move from the prior day. This move was narrower than the S&P 500's daily loss of 4.84%. On the other hand ...

Organon has acquired regulatory and commercial rights in the United States from Biogen for Tofidence, a biosimilar to Actemra for intravenous infusion. Tofidence, the first approved tocilizumab ...

The revision of the outlook to negative is due to the anticipation that Organon’s leverage will continue to be high over the next 12-18 months. This is attributed to limited near-term earnings growth ...